Therapeutic Antibodies

Therapeutical Antibodies– pharmaceuticals of the futureProgrammeFriday 4 November 2011, 14.00 – 16.30Symphogen A/S, Elektrovej Building 375, DK-2800 Lyngby14.00 WelcomeJens D. Mikkelsen, Chairman of ATV’s Scientific Group on Chemistry, LifeSciences and Geosciences14:0514:10Introduction from the host:CEO Kirsten Drejer, Symphogen A/STherapeutic Antibodies: a state-of-art overviewDr. John Haurum, VP Research, ImClone Systemts (New York, US)Dr. Haurum has held his position with ImClone Systems since January 2010, where heleads the antibody drug discovery and preclinical development project portfolio. ImCloneSystems develops targeted biologics therapies of cancer and in 2008 became a whollyownedsubsidiary of Eli Lilly.Before joining ImClone Systems, John Haurum was cofounder and Chief Scientific Officerof the Danish biotech company Symphogen since 2000. Dr. Haurum received hisdoctorate in Molecular Immunology from University of Oxford (UK); his MD from Universityof Aarhus (DK); and holds a Scandinavian International Management Institute (SIMI)diploma in Managing Medical Product Innovation. With his academic and industry experiencewithin immunology, biochemistry, infectious disease and oncology, and morethan 40 scientific publications, it is not surprising that Dr. Haurum has been consulting forseveral biotech companies in Denmark and abroad.14:45 Developing Optimized Antibodies for Cancer TherapyDr. Gregory P. Adams, co-leader of the Developmental Therapeutics Programat Fox Chase Cancer Centre and Associate Professor at Temple UniversitySchool of Medicine (Philadelphia, US)Dr. Adams’ current research is focused on developing antibody-based molecules totreat and detect cancer. In order to accomplish this, his lab is working to understand themanner by which antibodies target and penetrate tumours. The purpose is to generateantibodies that are more effective at this critical task. More specifically the lab is developingantibodies targeting ovarian, breast and renal cancers and aim to use these antibodiesas agents to deliver drugs and other agents to specific tumour sites in order to increasetheir efficacy and decrease toxicity to normal tissues.Dr. Adams has been working to develop antibodies for the detection and treatment ofcancer for his entire career. He joined the Fox Chase Cancer Centre right after he receivedhis Ph.D. in Immunology in 1991.15.10 Break

15:25 Manufacturing of Antibodies aimed at treatmentJesper Valbjørn, Senior Director CMC Operations, Genmab A/S (DK)Jesper Valbjørn joined Genmab A/S in 2006. Genmab is an international biotechnologycompany focused on developing fully human antibody therapeutics for the potentialtreatment of cancer. Jesper Valbjørn is heading CMC Operations with responsibility forthe CMC activities (chemistry, manufacturing and controls) in Genmabs projects fromearly phase to late phase validated commercial scale. Additionally the unit is responsiblefor the clinical drug supply logistics and preparation of CMC sections for regulatory filings.Jesper Valbjørn has 16 years of experience within CMC development in the biopharmaindustry with positions as project manager, manager and scientist at H. Lundbeck A/S,Dep. of Infectious Disease Immunology at Statens Serum Institut and Novo Nordisk.Jesper Valbjørn holds a MSc in Plant Biochemistry and is inventor of patents in the fieldof analytical science and process science.15:45 Recombinant Antibody Mixtures for Treatment of Cancer –from bench to bedsideDr. Ivan Horak, CSO and CMO, Symphogen (DK)Dr. Ivan Horak, a certified oncologist, is in charge of the scientific/medical area ofSymphogen – a Danish biopharmaceutical company developing unique antibody mixturesto treat cancer, infectious and autoimmune diseases.Before holding his position at Symphogen Dr. Horak has been President of Researchand Development and CSO of Enzon Pharmaceuticals Inc. He has also been CSO ofImmunomedics, where he was responsible for the development of novel antibodies.Dr. Horak has authored over 70 peer-reviewed publications and several book chapterswithin hematology, oncology, and immunology and has served on the editorial boards ofseveral scientific journals. He is Fellow of American College of Physicians and a memberof American Association for Cancer Research, American Society of Hematology, andAmerican Society Clinical Oncology.16:05 Future Perspectives on Antibody TherapyHanne Risager Romedahl, Vice President and Head of Immuno-Technology, Novo Nordisk (DK)Hanne R. Romedahl has been Head of Immunotechnology at Novo Nordisk since 2008,which is the unit responsible for developing therapeutic antibodies.Her fields of expertise evolve around therapeutic antibody development for autoimmunediseases, high throughput-based hybridoma and screening technology, and she has ascientific background in basic immunology focusing on dendritic cells and T-cells.Hanne R. Romedahl started her career at Novo Nordisk at the Biopharmaceuticals ResearchUnit, originally as a research scientist, and later as head of department ofScreening and Cell Technology. Prior to Novo Nordisk, she has been working at BioneerA/S and at the Technical University of Denmark, BioCentrum (currently named Departmentof Systems Biology). She obtained her PhD-degree in Immunology from DTU incollaboration with Michigan State University, USA.Hanne R. Romedahl is currently a member of the Biopharmaceuticals Research Unitmanagement team at Novo Nordisk.16.25 Closing remarksJens D. Mikkelsen

For more information, contact consultant Louise Rørbæk Heiberg, lrh@atv.dk